Thank you.
Back to you, Mr. Keon, I understand that the generic industry has a different take—I think it would be fair to say—on the amount of research that is being done by pharmaceutical companies in Canada and whether or not they in fact have met the 10% commitment that they made back in the 1980s as a condition of receiving extended intellectual property protection.
What's your association's view on that?